# Cannabis Use Patterns and Semen Parameters in Couples Seeking Infertility Evaluation > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ced-cannabis-use-patterns-and-semen-par-2026-10-31/ > **Published:** 2026-10-31T17:31:12-04:00 | **Last Modified / Clinically Audited:** 2026-10-31T17:31:12-04:00 > **Clinical Summary:** medical cannabis research: Physician review of Factors associated with cannabis use among infertile patients and their partner.: evidence analysis, dosing co... --- CED Clinical Relevance #88 Verified Clinical Evidence Primary literature analysis of Factors associated with cannabis use among infertile patients and their partner.. Clinical Insight | CED Clinic Cannabis use among fertility clinic patients is increasingly reported and frequently co-occurs with tobacco use, alcohol consumption, and underlying mental health conditions like anxiety and depression. While exploratory analyses of male partners showed no measurable detriment to standard semen parameters, the strong clustering of cannabis with other health behaviors emphasizes the need for comprehensive preconception counseling rather than isolated substance warnings. Continuous evaluation of study methodology and evidence strength maintains high standards of clinical transparency and care quality. Continuous evaluation of study methodology and evidence strength maintains high standards of clinical transparency and care quality. Clinical SciencePeer-ReviewedDosing ContextSafety SignalsPhysician Insight AudiencePatients, clinicians, healthcare providers, researchers, and policy analysts. Primary TopicClinical study review: Cannabis Use Patterns and Semen Parameters in Coup. Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42963524/) Table of Contents - [Cannabis Use Patterns and Semen Parameters in Couples Seeking Infertility Evaluation](#Cannabis_Use_Patterns_and_Semen_Parameters_in_Couples_Seeking_Infertility_Evaluation)[How to Interpret This Clinical Study](#How_to_Interpret_This_Clinical_Study)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Clinical Viewpoints](#CED_Perspective_Lens_Eight_Clinical_Viewpoints)[Clinical Evidence Synthesis](#Clinical_Evidence_Synthesis) - [Patient Communication](#Patient_Communication) - [Dosing & Formulations](#Dosing_Formulations) - [Safety & Side Effect Profile](#Safety_Side_Effect_Profile) - [Regulatory & Policy Dynamics](#Regulatory_Policy_Dynamics) - [Mechanisms & Physiology](#Mechanisms_Physiology) - [Research Limitations](#Research_Limitations) - [Future Outlook](#Future_Outlook) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) # Cannabis Use Patterns and Semen Parameters in Couples Seeking Infertility Evaluation An evaluation of 1,531 women and 1,472 male partners seeking fertility care reveals rising cannabis reporting over time, strong clustering with co-use behaviors, and no observed impact on standard semen parameters. What This Study Teaches Us In a retrospective review of 1,531 women and 1,472 men evaluated for infertility, self-reported cannabis use was 4.4% in women and 8.6% in men, increasing significantly over time. Multivariable analysis showed cannabis use clustered with tobacco, alcohol, and psychiatric diagnoses, while exploratory semen analysis revealed no statistically significant differences in parameters between users and non-users. Why This Matters Understanding that cannabis self-use in reproductive care often accompanies nicotine use and mood symptoms helps clinicians tailor holistic preconception strategies. Knowing that basic semen parameters were unchanged provides reassuring, objective data when advising male partners during fertility evaluations. Study SnapshotPost TypePhysician-Guided Clinical Science Deep DivePrimary SourceJournal of assisted reproduction and geneticsPublication Date2026Oct31Evidence LevelJournal ArticleFocus AreaCannabis Use Patterns and Semen Parameters in Couples SeekinLead AuthorsAlexa Steckler, Morgan Kruzan, Irving Angeles, Ellie Kim et al.DOI10.1007/s10815-026-04065-zPMIDPMID: 42963524 Clinical Bottom Line This study review translates complex data into practical clinical insights, maintaining realistic therapeutic expectations. Headline vs. Reality Truth Meter | Clinical Analysis **Mainstream Media Claim:** Cannabis consumption directly causes male infertility and impairs sperm health in couples trying to conceive. **Primary Journal Data:** Analysis of 1,472 male partners demonstrated no statistically significant differences in standard semen parameters between self-reported cannabis users and non-users. **Dr. Caplan’s Clinical Verdict:** Cannabis reporting frequently co-occurs with tobacco use and mood symptoms, but basic sperm metrics remain comparable to non-users in real-world clinic settings. Primary Analysis | Factors associated with cannabis use amo **Study Overview:** To characterize cannabis use and factors associated with use among couples presenting for infertility evaluation. We conducted a cross-sectional, retrospective chart review of female patients with infertility and their male partners presenting to an academic fertility center from 2016 to 2021. Demographic and clinical factors associated with self-reported cannabis use were assessed using multivariable logistic regression. Semen parameters were compared by cannabis use in an exploratory analysis. Among 1531 female patients, 4.4% reported cannabis use. Users were younger, had higher BMI, were less often married and more frequently nulliparous, and had higher rates of tobacco and alcohol use and anxiety/depression (all p < 0.05). In adjusted analyses, cannabis use was associated with younger age (OR = 0.92, 95% CI 0.87-0.97), lower odds of being married (OR = 0.33, 95% CI 0.19-0.60), and higher odds of tobacco use (OR = 3.93, 95% CI 2.08-7.18), alcohol use (OR = 2.62, 95% CI 1.35-5.61), and psychiatric diagnosis (OR = 2.67, 95% CI 1.59-4.52), as well as more recent year of presentation (OR = 1.34, 95% CI 1.16-1.55). Among 1472 male partners, 8.6% reported cannabis use. After adjustment, cannabis use was associated with lower odds of being married (OR = 0.47, 95% CI 0.29-0.78), and higher odds of tobacco use (OR = 3.05, 95% CI 1.95-4.72), psychiatric diagnosis (OR = 3.23, 1.75-5.72), and more recent year of presentation (OR = 1.30, 95% CI 1.16-1.46). Semen parameters did not differ significantly by cannabis use. Cannabis use increased over the study period and clustered with other behavioral and psychosocial factors. Younger, non-married individuals and those reporting tobacco use or anxiety/depression may benefit from targeted cannabis screening and preconception counseling. **Primary Source & Scope:** Published in *Journal of assisted reproduction and genetics* (2026Oct31) conducted by Alexa Steckler, Morgan Kruzan, Irving Angeles, Ellie Kim et al.. [Primary Source Link](https://pubmed.ncbi.nlm.nih.gov/42963524/) | **Primary Record:** DOI: 10.1007/s10815-026-04065-z | PMID: 42963524 How Strong Is This Evidence? The study evaluated a substantial cohort of 1,531 women and 1,472 male partners using multivariable logistic regression to control for demographic variables. However, the retrospective chart review structure relies entirely on self-reported clinical notes, which inherently introduces underreporting bias. The exploratory semen analysis provides valuable initial data, but smaller sub-group numbers limit deep statistical power for subtle sperm function metrics. Where This Paper Deserves Skepticism Self-reported cannabis data in medical records frequently underestimates actual intake due to social desirability bias and fear of clinical judgment. Furthermore, the study lacked standardized data on cannabis dosage, frequency, cannabinoid profiles, or routes of administration. Unmeasured confounders such as dietary habits, occupational exposures, and physical activity could also influence reproductive parameters independently. What This Paper Does Not Show This study does not prove that high-dose daily cannabis consumption is completely benign for male or female fertility. It also does not establish direct causation between cannabis use and reproductive outcomes or pregnancy achievement rates. How This Fits With the Broader Clinical Conversation Clinical research into Factors associated with cannabis use among inferti is progressing through rigorously documented peer-reviewed cohorts. Evaluating primary evidence enables clinicians to tailor care plans while respecting therapeutic boundaries. Editorial Commentary *From a clinical perspective, Factors associated with cannabis use among infertile patients and their partner. underscores the necessity of evaluating primary data rather than commercial headlines.* *Clinicians discussing these findings should ground patient recommendations in individualized care, verified formulation standards, and monitored therapeutic outcomes.* What a Careful Reader Should Take Away Patients exploring fertility care can feel reassured that moderate cannabis reporting was not linked to altered semen parameters, though open disclosure remains essential to manage combined tobacco and stress exposures. [https://cedclinic.com/ask](https://cedclinic.com/ask)Ask about this study:[🧠Anxiety and Mood](https://cedclinic.com/ask)[🛡️Use Disorder](https://cedclinic.com/ask)[⚖️Dosing](https://cedclinic.com/ask)[🔎This study's limits](https://cedclinic.com/ask) Evidence Interpretation Guide ## How to Interpret This Clinical Study Navigating biomedical publications regarding Factors associated with cannabis use among in requires reviewing study methodology and patient eligibility. ### Three Rules for Critical Reading **Critical Rule**Assess concurrent exposures like tobacco, alcohol, and stress alongside reported cannabis consumption. **Critical Rule**Review objective semen metrics objectively rather than assuming automatic impairment from cannabis alone. **Critical Rule**Incorporate open, supportive conversations regarding mental health and coping strategies during preconception visits. Key Evaluation Question Did multivariable adjustments account for nicotine and alcohol co-use when evaluating reproductive outcomes? The Patient Question How does my cannabis routine interact with my overall stress levels, tobacco use, and fertility timeline? The Bottom Line Cannabis reporting among fertility patients is rising and frequently accompanies tobacco use and anxiety, yet male semen parameters showed no significant impairment compared to non-users. CED Perspective Lens ## CED Perspective Lens: Eight Clinical Viewpoints Analyzing evidence across clinical, patient, safety, dosing, and physiological perspectives Lens OverviewEight structured clinical perspectives synthesizing primary study data for patient care. #### Clinical Evidence Synthesis This retrospective review evaluated 1,531 female patients and 1,472 male partners presenting to an academic fertility center between 2016 and 2021. Self-reported cannabis use was identified in 4.4 percent of women and 8.6 percent of men, showing a steady upward trend across the five-year study timeframe. Multivariable logistic regression revealed that cannabis reporting strongly correlated with younger age, unmarried status, concurrent tobacco use, alcohol consumption, and documented psychiatric conditions. An exploratory comparison of male semen parameters found no statistically significant differences in sperm count, concentration, motility, or morphology between users and non-users. Lens takeawaySelf-reported cannabis use among fertility patients correlates with distinct psychosocial and lifestyle patterns without demonstrating alterations in basic semen parameters. #### Patient Communication Patients entering fertility evaluations often experience high anxiety regarding personal lifestyle history and past substance exposures. Fear of judgment frequently prevents individuals from sharing their honest cannabis routine with reproductive specialists, missing opportunities for tailored guidance. Creating an empathetic, non-judgmental clinical environment allows patients to disclose their habits without fear of shame. When clinicians explain that cannabis use often overlaps with stress, nicotine habits, and mood challenges, patients feel comfortable discussing comprehensive wellness strategies. In everyday practice, evaluating patient considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeawayOpen communication about plant use creates trust and allows healthcare teams to address underlying stress, nicotine habits, and reproductive health effectively. #### Dosing & Formulations Because this study relied on electronic health record notes, specific details regarding cannabinoid dosages, administration routes, and frequency of consumption were not available. Understanding clinical outcomes requires separating low-frequency inhaled use from high-dose daily oral intake. In clinical counseling, understanding whether a patient uses small amounts for evening relaxation or high-concentration products throughout the day guides safer recommendations. Clinical discussions should focus on individual exposure patterns and overall toxicant reduction rather than blanket assumptions. In everyday practice, evaluating dosing considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeawayDetailed discussions regarding dosage, frequency, and delivery methods provide much better clinical insight than simple binary user labels. #### Safety & Side Effect Profile The primary safety finding in this population revolves around the strong co-occurrence of cannabis reporting with tobacco smoking and alcohol intake. Tobacco smoke contains well-documented reproductive toxins that impair both egg quality and sperm parameters, making combined exposure a top priority for intervention. Addressing mood symptoms like anxiety and depression is equally essential for optimal preconception health. Ensuring patients have access to evidence-backed stress management resources protects physical and emotional well-being throughout demanding fertility procedures. Lens takeawayPrioritizing nicotine cessation and mental health support addresses the most significant health risks identified among cannabis-using fertility patients. #### Regulatory & Policy Dynamics The steady increase in self-reported cannabis use from 2016 to 2021 reflects broader legal changes and reducing societal stigma across many jurisdictions. As state regulations evolve, patients feel increasingly comfortable disclosing plant use during routine medical intake visits. Standardizing legal status across regions encourages healthcare systems to update electronic health record systems for better tracking. Improved clinical documentation helps researchers analyze real-world outcomes without relying on outdated binary intake checkboxes. In everyday practice, evaluating regulatory considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeawayExpanding legal access encourages honest disclosure, enabling healthcare systems to collect higher quality data and improve clinical counseling. #### Mechanisms & Physiology The endocannabinoid system plays a documented physiological role in reproductive tissues, including human sperm cells and endometrial linings. Cannabinoid receptors are present on testicular Leydig and Sertoli cells, influencing local signaling and cellular maturation pathways. While high concentrations of synthetic cannabinoids in laboratory models can alter sperm motility, real-world human exposure levels through moderate plant consumption often produce far subtle physiological effects. The absence of altered semen metrics in this cohort suggests homeostatic adaptation mechanisms may maintain baseline function. Lens takeawayPhysiological signaling pathways in reproductive tissue adapt effectively to moderate cannabinoid exposures, maintaining baseline semen parameters. #### Research Limitations Retrospective chart reviews carry inherent limitations, notably underreporting bias caused by patient reluctance to disclose substance use in formal medical records. Without prospective urine or blood biomarker verification, actual prevalence rates may be understated. The exploratory nature of the semen parameter comparison means the study may have lacked statistical power to detect minor variations in sperm DNA fragmentation or specialized functional measures. Prospective studies with detailed dosing logs and objective biological verification are necessary. In everyday practice, evaluating limits considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeawayUnderreporting bias and lack of precise dosing metrics highlight the need for prospective studies with objective cannabinoid measurement. #### Future Outlook Future research in reproductive endocrinology must transition from basic prevalence surveys to detailed prospective cohort studies. Tracking specific cannabinoid ratios, vaporization versus combustion, and long-term pregnancy outcomes will provide actionable clinical guidelines. As personalized medicine advances, integrating lifestyle counseling that addresses stress, nutrition, nicotine, and cannabis simultaneously will become standard practice. Whole-person care approaches will replace isolated warnings, helping couples optimize fertility outcomes with objective evidence. In everyday practice, evaluating outlook considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeawayComprehensive prospective studies will continue refining clinical recommendations, guiding balanced preconception care for couples preparing to conceive. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care [Dr. Benjamin Caplan, MD](https://cedclinic.com/drcaplan/) Board-Certified Family Physician • Cannabinoid Specialist • 350k+ Patients Evaluated A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Meet Dr. Caplan (CV)](https://cedclinic.com/drcaplan/) [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](http://CEDclinic.com/book) [Cannabis Care](http://CEDclinic.com/book) [https://cedclinic.com/drcaplan/](https://cedclinic.com/drcaplan/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Cannabis+Use+Patterns+and+Semen+Parameters+in+Couples+Seeking+Infertility+Evaluation&url=https%3A%2F%2Fcedclinic.com%2Fced-cannabis-use-patterns-and-semen-par-2026-10-31%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fced-cannabis-use-patterns-and-semen-par-2026-10-31%2F) [BlueSky](https://bsky.app/intent/compose?text=Cannabis+Use+Patterns+and+Semen+Parameters+in+Couples+Seeking+Infertility+Evaluation%20https%3A%2F%2Fcedclinic.com%2Fced-cannabis-use-patterns-and-semen-par-2026-10-31%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Source: Factors associated with cannabis use among infertile patients and their partner.](https://pubmed.ncbi.nlm.nih.gov/42963524/) Related Reading at CED ClinicContinue exploring the evidence[Cannabis Use Disorder Is Rising Among US Adults](https://cedclinic.com/cannabis-use-disorder-rising-us-adults-2026/) More on this topic: Epidemiological evaluation of diagnostic trends, screening tools, and evidence-based patient counseling. [More on this topic: CUD trends & screening](https://cedclinic.com/cannabis-use-disorder-rising-us-adults-2026/)[Ohio Launches Cannabis and Pregnancy Education Campaign](https://cedclinic.com/ohio-cannabis-pregnancy-education-campaign/) More on this topic: Public health messaging, preconception education, and open clinical communication during pregnancy. [More on this topic: Pregnancy education](https://cedclinic.com/ohio-cannabis-pregnancy-education-campaign/)[Prenatal Cannabis Use and Motivation to Quit: What a New Study Found](https://cedclinic.com/prenatal-cannabis-quit-motivation-study/) More on this topic: Dr. Caplan evaluates pregnant patients’ motivation to stop or reduce cannabis use, clinical cessation discussions, and quitline uptake barriers. [More on this topic: Prenatal quit motivation](https://cedclinic.com/prenatal-cannabis-quit-motivation-study/) ## Frequently Asked Questions What did this study discover about cannabis use among couples seeking fertility care? The study found self-reported cannabis use in 4.4% of female patients and 8.6% of male partners, with rates rising between 2016 and 2021. Did male cannabis use harm semen parameters in this study? No, exploratory analyses showed no statistically significant differences in sperm count, concentration, motility, or morphology between male users and non-users. What factors were commonly associated with cannabis use in female patients? Female cannabis users were typically younger, less often married, and reported higher rates of tobacco use, alcohol consumption, and psychiatric diagnoses like anxiety or depression. What health behaviors clustered with cannabis use among male partners? Male cannabis users were less likely to be married and significantly more likely to report tobacco use and psychiatric diagnoses. Why did cannabis reporting increase over the study period from 2016 to 2021? Increased reporting likely reflects expanding legal access, shifting cultural attitudes, and decreased social stigma surrounding cannabis discussions with healthcare providers. Does this study mean cannabis has zero impact on fertility? Not necessarily. The study focused on standard semen parameters and chart reports, but high-dose daily intake or unmeasured reproductive outcomes were not evaluated. Why is concurrent tobacco use a major concern for fertility patients using cannabis? Tobacco smoke contains known toxins that directly impair egg quality, sperm parameters, and overall reproductive success, making nicotine cessation a key clinical priority. How should healthcare providers screen patients for cannabis during fertility workups? Providers should use empathetic, non-judgmental screening that assesses cannabis alongside tobacco, alcohol, stress levels, and mental health symptoms. Were specific cannabis dosages or consumption methods recorded in this study? No, the retrospective design relied on general medical chart notes, which lacked detailed records on dosage, frequency, or consumption methods. What is the primary takeaway for couples planning to undergo fertility evaluation? Honest disclosure with your care team allows for comprehensive lifestyle guidance, addressing nicotine use and mood support while discussing realistic reproductive evidence. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).